• Vivani signed a new agreement allowing Novo Nordisk to run a non-exclusive internal evaluation of its NPM-139 semaglutide implant.
• Deal includes no exclusivity for NPM-139 or Vivani’s NanoPortal platform, leaving room for other partners or parallel development.
• Vivani plans to start a randomized Phase 1 first-in-human study in mid-2026, using Wegovy injections as the active comparator.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607072312OMX_____CNEWS_DE_GNW9758812_de) on July 08, 2026, and is solely responsible for the information contained therein.